Gilead teams with startup to turn machine learning on fatty liver disease

Aiming to generate fresh data to run through its machine learning system, a startup is embarking on a three-year collaboration with one of biotech's biggest players in the fatty liver disease known as NASH.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.